Advertisement

Comparative Results Obtained in the Treatment of Acute Leukemia

  • M. D. DowlingJr.
  • M. Haghbin
  • T. S. Gee
  • B. Cunningham
  • C. T. C. Tan
  • B. D. Clarkson
  • J. H. Burchenal
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 43)

Abstract

The current programs used to treat acute leukemia at Memorial-Sloan Kettering Cancer Center are determined on the basis of morphologic criteria and age. The following report describes the regimens used and the current experience at this Center. Although age may be an important factor in the ultimate response of the patient, the morphologic characteristics of the disease govern the therapeutic approach. In acute lymphoblastic leukemia (ALL), the L-2 protocol is used. In the acute non-lymphoblastic leukemias, myeloblastic, myelomonoblastic and monoblastic (AML), the L-6 protocol is followed. The age division is based on practical lines in that there are both adult and pediatric leukemic groups. However, there are only minor differences in the protocols due mainly to practical rather than real considerations.

Keywords

Leukemic Cell Acute Lymphoblastic Leukemia Acute Leukemia Central Nervous System Disease Remission Induction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aur,, R., Hustu,, O., Verzosa,, M., Simone,, J.: A comparative study of “prophylactic” craniospinal irradiation in 94 children with acute lymphocytic leukemia. Proc. Amer. Ass. Cancer Res. 12, 19 (1971).Google Scholar
  2. 2.
    Aur, R. J. A., Simone, J., Hustu, H. O., Walters, T., Burella, L., Pratt, C., Pindel, D.: Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood (in press).Google Scholar
  3. 3.
    Bernard, J., Jacquillart, C., Weil, M., Boiron, M., Tanzer, J.: Present results on donaurubicin (rubidomycin, Donaumycin). Recent Results in Cancer Research. Advances in the treatment of acute (Blastic) leukemias, p. 3. Ed.: G. Mathe. New York: Springer 1970.Google Scholar
  4. 4.
    Burchenal, J. H.: Clinical evaluation and future prospects of asparaginase. Recent Results in Cancer Research. Advances in the treatment of acute (Blastic) leukemias, p. 20. Ed.: G. Mathe. New York: Springer 1970.Google Scholar
  5. 5.
    Clarkson, B. D., Fried, J., Strife, A., Sarai, Y., Ota, K., Ohkita, T., Masuda, R.: Studies of cellular proliferation in human leukemia. IV. Behavior of normal hematopoietic cells in three adults with acute leukemia given continuous infusions of -thymidine. Cancer (Philad.) 26, 1 (1970).CrossRefGoogle Scholar
  6. 6.
    Clarkson, B. D., Fried, J.: Changing concepts of treatment in acute leukemia. Medical Clinics of North America, vol. 55, p. 561. Philadelphia-London-Toronto: W. B. Saunders Company 1971.Google Scholar
  7. 7.
    Clarkson, B., Krakoff, I., Burchenal, J., Karnofsky, D., Golbey, R., Oettgen, H., Dowling, M., Lipton, A.: Clinical results of treatment with E. Coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer (Philad.) 25, 279 (1970).Google Scholar
  8. 8.
    Clarkson, B. D., Ohkita, T., Ota, K., Fried, J.: Studies of cellular proliferation in human leukemia. I. Estimation of growth rates of leukemic and normal hematopoietic cells in two adults with acute leukemia given single injections of tritiated thymidine. J. clin. Invest. 46, 506 (1967).Google Scholar
  9. 9.
    Freireich, E. J., Bodey, G. P., Hart, J. S., Rodriguez, V., Whitecar, J. P., Frei, E. III.: Remission induction in adults with acute myelogenous leukemia. Recent Results in Cancer Research. Advances in the treatment of acute (Blastic) leukemias, p. 85. Ed.: G. MATHE. New York: Springer 1970.Google Scholar
  10. 10.
    Gee, T. S., Yu K.-P., Clarkson, B. D.: Treatment of adult acute leukemia with arabinosyl cytosine and thioguanine. Cancer (Philad.) 23, 1019 (1969).CrossRefGoogle Scholar
  11. 11.
    Haghbin, M., Tan, C., Gee, T., Dowling, M., Clarkson, B., Sidhu, J., Murphy, M. L., Burchenal, J., Sykes, M.: Sequential intensive drug therapy in acute lymphoblastic leukemia (ALL) and leukosarcoma (LSA). Proc. Amer. Ass. Cancer Res. 12, 122 (1971).Google Scholar
  12. 12.
    Henderson, E. S.: Treatment of acute leukemia. Sem. Hemat. 6, 271 (1969).Google Scholar
  13. 13.
    Henderson, E. S., Samaha, R. J.: Evidence that drugs in multiple combinations have materially advanced the treatment of human malignancies. Cancer Res. 29, 2272 (1969).Google Scholar
  14. 14.
    Holland, J. F.: Who should treat acute leukemia ? J. Amer. med. Ass. 209, 1511 (1969).CrossRefGoogle Scholar
  15. 15.
    Holland, J. F., Glidewell, O.: Complementary chemotherapy in acute leukemia. Recent Results in Cancer Research. Advances in the treatment of acute (Blastic) leukemias, p. 95. Ed.: G. MATHE. New York: Springer 1970.Google Scholar
  16. 16.
    Leukemia and Hematosarcoma Cooperative Group of the European Organisation for Research on the Treatment of Cancer (E. O. R. T. C.): Rubidomycin (or daunomycin): A clinical evaluation. Recent Results in Cancer Research. Advances in the treatment of acute (Blastic) leukemias, p. 9. Ed.: G. Mathe. New York: Springer 1970.Google Scholar
  17. 17.
    Mathe, G., Amiel, J. L., Schwarzenberg, L., Schneider, M., Cattan, A., Hay at, M., De Vassal, F., Schlumberger, J. R.: Methods and strategy for the treatment of acute lymphoblastic leukemia. Recent Results in Cancer Research. Advances in the treatment of acute (Blastic) leukemias, p. 109. Ed.: G. Mathe. New York: Springer 1970.Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1973

Authors and Affiliations

  • M. D. DowlingJr.
    • 1
  • M. Haghbin
    • 1
  • T. S. Gee
    • 1
  • B. Cunningham
    • 1
  • C. T. C. Tan
    • 1
  • B. D. Clarkson
    • 1
  • J. H. Burchenal
    • 1
  1. 1.Division of Chemotherapy ResearchSloan-Kettering Institute for Cancer ResearchNew YorkUSA

Personalised recommendations